Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
China · Delayed Price · Currency is CNY 56.02
-0.83 (-1.46%)
Apr 17, 2026, 3:04 PM CST
SHE:002653 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 4,354 | 3,693 | 3,335 | 2,998 | 2,765 |
Other Revenue | 33.62 | 28.6 | 19.94 | 17.03 | 8.46 |
| 4,388 | 3,721 | 3,355 | 3,015 | 2,773 | |
Revenue Growth (YoY) | 17.91% | 10.92% | 11.27% | 8.72% | -16.71% |
Cost of Revenue | 1,266 | 1,062 | 971.25 | 925.27 | 946.88 |
Gross Profit | 3,121 | 2,660 | 2,384 | 2,090 | 1,826 |
Selling, General & Admin | 2,090 | 1,763 | 1,521 | 1,464 | 1,331 |
Research & Development | 804.29 | 624.13 | 516.67 | 447.87 | 431.4 |
Other Operating Expenses | 28.42 | 8.6 | 13.98 | 35.82 | 26.28 |
Operating Expenses | 2,922 | 2,398 | 2,052 | 1,948 | 1,789 |
Operating Income | 199.62 | 262.03 | 331.58 | 141.57 | 37.6 |
Interest Expense | -32.53 | -37.84 | -42.28 | -50.91 | -27.16 |
Interest & Investment Income | 25.85 | 140.71 | 19.33 | 235.41 | 426.35 |
Currency Exchange Gain (Loss) | -1.08 | 0.76 | -0.06 | 0.97 | -0.17 |
Other Non Operating Income (Expenses) | 2.35 | -1.81 | -0.63 | 1.13 | -1.1 |
EBT Excluding Unusual Items | 194.2 | 363.84 | 307.93 | 328.16 | 435.52 |
Gain (Loss) on Sale of Investments | -17.15 | 0.08 | -60.47 | - | - |
Gain (Loss) on Sale of Assets | -22.27 | 31.1 | -0.28 | -0 | -0.13 |
Asset Writedown | -11.36 | -83.19 | -13.02 | -0.84 | -0.62 |
Other Unusual Items | 130.15 | 151.12 | 68.37 | 39.3 | 75.97 |
Pretax Income | 273.58 | 462.95 | 302.52 | 366.61 | 510.74 |
Income Tax Expense | 14.02 | -3.25 | 6.96 | -25.1 | -6.84 |
Earnings From Continuing Operations | 259.56 | 466.2 | 295.56 | 391.71 | 517.58 |
Minority Interest in Earnings | 0.02 | -70.74 | -0.45 | -114.64 | -172.52 |
Net Income | 259.58 | 395.46 | 295.11 | 277.07 | 345.06 |
Net Income to Common | 259.58 | 395.46 | 295.11 | 277.07 | 345.06 |
Net Income Growth | -34.36% | 34.00% | 6.51% | -19.70% | -45.80% |
Shares Outstanding (Basic) | 1,129 | 1,130 | 1,093 | 1,066 | 1,078 |
Shares Outstanding (Diluted) | 1,129 | 1,130 | 1,093 | 1,066 | 1,078 |
Shares Change (YoY) | -0.11% | 3.37% | 2.57% | -1.17% | -0.07% |
EPS (Basic) | 0.23 | 0.35 | 0.27 | 0.26 | 0.32 |
EPS (Diluted) | 0.23 | 0.35 | 0.27 | 0.26 | 0.32 |
EPS Growth | -34.29% | 29.63% | 3.85% | -18.75% | -45.76% |
Free Cash Flow | 454.03 | 1.39 | 58.57 | -605.62 | -667.14 |
Free Cash Flow Per Share | 0.40 | 0.00 | 0.05 | -0.57 | -0.62 |
Dividend Per Share | 0.267 | 0.415 | 0.200 | - | 0.185 |
Dividend Growth | -35.66% | 107.50% | - | - | -50.22% |
Gross Margin | 71.14% | 71.47% | 71.05% | 69.31% | 65.86% |
Operating Margin | 4.55% | 7.04% | 9.88% | 4.70% | 1.36% |
Profit Margin | 5.92% | 10.63% | 8.80% | 9.19% | 12.44% |
Free Cash Flow Margin | 10.35% | 0.04% | 1.75% | -20.09% | -24.06% |
EBITDA | 462.44 | 502.03 | 544.25 | 317.33 | 183.93 |
EBITDA Margin | 10.54% | 13.49% | 16.22% | 10.52% | 6.63% |
D&A For EBITDA | 262.82 | 240 | 212.67 | 175.76 | 146.33 |
EBIT | 199.62 | 262.03 | 331.58 | 141.57 | 37.6 |
EBIT Margin | 4.55% | 7.04% | 9.88% | 4.70% | 1.36% |
Effective Tax Rate | 5.12% | - | 2.30% | - | - |
Revenue as Reported | 4,388 | 3,721 | 3,355 | 3,015 | 2,773 |
Advertising Expenses | - | - | - | - | 3.74 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.